CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
June 13, 2024 08:15 ET
|
CERo Therapeutics Holdings, Inc.
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO)...
浩鼎啟動OBI-992一/二期臨床試驗
June 12, 2024 05:55 ET
|
OBI Pharma Inc.
OBI-992以TROP2為標靶的ADC 研究目的在評估治療多種實體腫瘤的安全性和有效性 台灣台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎 (4174.TWO)今（12）日宣布，正式啟動OBI-992的人體一/二期臨床試驗。OBI-992係浩鼎自行研發，以TROP2為標靶所設計的抗體藥物複合體(antibody-drug conjugate,...
浩鼎启动OBI-992一/二期临床试验
June 12, 2024 05:55 ET
|
OBI Pharma Inc.
OBI-992以TROP2为标靶的ADC 研究目的在评估治疗多种实体肿瘤的安全性和有效性 台湾台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎 (4174.TWO)今（12）日宣布，正式启动OBI-992的人体一/二期临床试验。 OBI-992系浩鼎自行研发，以TROP2为标靶所设计的抗体药物复合体(antibody-drug...
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy
June 12, 2024 05:55 ET
|
OBI Pharma Inc.
OBI-992 phase 1/2 study initiation
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland
June 12, 2024 05:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano, Switzerland – June 12, 2024 – Helsinn Group (“Helsinn”), a global...
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
June 10, 2024 10:17 ET
|
Sermonix Pharmaceuticals Inc.
In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumorsPhase 3 ELAINE-3 study is currently investigating...
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
June 10, 2024 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
June 10, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors
June 10, 2024 04:00 ET
|
Cumulus Oncology
EDINBURGH, Scotland, June 10, 2024 (GLOBE NEWSWIRE) -- Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to...
Macomics Announces Appointment of Simon Dew as New Chief Business Officer
June 10, 2024 04:00 ET
|
Macomics Limited
Macomics continues to expand its leadership team to accelerate the development of first-in-class macrophage-targeted therapiesSimon Dew brings over 25 years of experience in pharmaceutical business...